SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-100780
Filing Date
2023-09-14
Accepted
2023-09-14 16:04:55
Documents
15
Period of Report
2023-09-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2317653d13_8k.htm   iXBRL 8-K 34080
2 EXHIBIT 10.1 tm2317653d13_ex10-1.htm EX-10.1 65525
3 EXHIBIT 99.1 tm2317653d13_ex99-1.htm EX-99.1 15151
  Complete submission text file 0001104659-23-100780.txt   353467

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20230911.xsd EX-101.SCH 3303
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20230911_def.xml EX-101.DEF 26897
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20230911_lab.xml EX-101.LAB 36508
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20230911_pre.xml EX-101.PRE 25521
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2317653d13_8k_htm.xml XML 4906
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 231255148
SIC: 2834 Pharmaceutical Preparations